Introduction
============

Sphingolipids are ubiquitous components of the eukaryotic cell membrane that play important roles in the regulation of many cellular processes ([@B33]; [@B141]). Among these molecules, sphingosine 1-phosphate (S1P) is a bioactive lipid with a variety of physiological roles across a broad range of organisms ([@B109]). S1P is produced by the phosphorylation of sphingosine, a reaction catalyzed by an enzyme, sphingosine kinase (SphK), present in two isoforms, SphK1 and 2. S1P degradation involves a cleavage by S1P lyase (SPL) ([@B45]). In general, when phosphorylated, this lipid is secreted in the plasma, mainly by red blood cells, platelets, fibroblasts, and vascular endothelial cells (ECs, [@B114]; [@B49]; [@B83]; [@B122]; [@B31]). In addition, extracellular SphK1 released from these cells may also contribute to S1P synthesis ([@B123]).

The activation of SphK1 and 2, and the consequent S1P generation/secretion have a crucial role in many cellular signaling cascades and pathological processes. In particular, their role has been widely studied in angiogenesis, in cancer development/progression and in immune and inflammatory responses ([@B50]). However, the SphK/S1P axis has received a special attention from cardiovascular scientists because implicated in the cardiovascular system development and functioning. The latter encompasses the modulation of heart rate, cardiac contractility, and vascular tone ([@B87]). All these effects are mediated by the binding to specific G protein-coupled receptors (GPCRs), called S1PRs ([@B41]; [@B20]; [@B107]; [@B120]). Since an increasing body of experimental evidence supports the notion that activating the SphK/S1P-S1PR system protects both the heart and the vasculature, several synthetic S1P analogs have been previously designed ([@B86]). Of note, one of them, Fingolimod, or FTY720 (a Novartis proprietary compound) is currently approved and used in clinical practice to treat neurological degenerative disorders, such as multiple sclerosis ([@B86]).

Given the current availability of compounds, such as Fingolimod, it is now more feasible, and should be even more attractive, to test the impact of agonists of the SphK/S1P-S1PR axis in the context of clinically relevant cardiovascular disorders, as in the recent case of a study that demonstrated an increase in myocardial salvage and a decrease in adverse post-infarction remodeling with Fingolimod in a porcine model of ischemia-reperfusion injury ([@B99]).

Here, we will review the mechanisms by which SphKs modulate S1P generation and secretion in different cardiovascular compartments. Then, we will focus on the pathophysiological role exerted by SphK/S1P-S1PRs axis in the circulatory system. Finally, we will describe how S1PRs agonism and antagonism can improve outcome in cardiac disease states, such as post-ischemic heart failure (HF).

Structure and Function of Sphingosine Kinases
=============================================

Structure of SphKs
------------------

The SphKs are members of a family of enzymes that includes the diacylglycerol (DAG) and the ceramide kinases, all of which are able to generate bioactive lipids ([@B133]). Currently, two isoforms (SphK1 and 2) have been cloned and characterized, and the genes encoding for these two enzymes are localized on different chromosomes---sphk1 gene is on chromosome 17, whereas sphk2 gene is on chromosome 19---and encode for several splicing variants ([@B45]; [@B1]). SphK1 was originally purified from rat and show a high degree of homology with the mouse and human enzyme ([@B56]; [@B78]). The second isoform, SphK2, was cloned and characterized from mouse and human by Spiegel and colleagues ([@B63]). At the structural level, SphK1, in homology with SphK2, is composed of an N-terminal (NT) and a C-terminal (CT) domain, with the catalytic one located in a cleft at the interdomain junction. Both structures appear to have an homology because they contain five conserved domains, including an adenosine triphosphate (ATP)-binding motif that allows the transfer of a γ-phosphoryl group from the ATP to the [D]{.smallcaps}-*erythro*-sphingosine, to generate the S1P ([@B73]; [@B78]). However, while SphK2 presents a nuclear localization signal (NLS) in the NT and a nuclear exportation signal (NES) in the CT, SphK1 lacks these sequences. Importantly, their presence within the SphK2 structure increases also the number of amino acids required for the enzyme composition. In fact, SphK1 consists of 384 amino acids (42.5 kDa), whereas SphK2 presents with 618 amino acids (65.2 kDa) ([@B63]; [@B80]). Moreover, based on kinetic studies performed *in vitro* and *in vivo*, both SphKs cannot only phosphorylate sphingosine in a similar manner, but they can also phosphorylate the immunomodulatory drug FTY720 (Fingolimod). However, SphK2 appear to be more efficient in doing so than SphK1 ([@B7]; [@B85]). Due to this property, it has been suggested that only SphK2 is required for metabolic activation of this drug. In fact, FTY720, that is able to cause lymphopenia, loses its effect only in mice lacking SphK2, but not in mice in which SphK1 is downregulated ([@B2]; [@B54]). For all these very reasons, it appears crystal-clear that, based on their structure, both the kinases can have different functions and localization (please, see more below). However, as shown by previous studies, these kinases have overlapping vital functions. In this regard, although knockout mouse models for either SphK1 or SphK2 develop normally, the genetic deletion of both isoforms results in fetal death due to alterations in vasculogenesis and severe bleeding ([@B2]; [@B75]; [@B74]).

Subcellular Localization of SphKs
---------------------------------

Concerning the localization of the two enzymes, it has been reported that SphK1 predominantly resides in the cytoplasm ([@B132]; [@B88]), and it can translocate to the plasma membrane upon cell stimulation ([@B89]). Therefore, S1P generated by SphK1 can be exported outside the cells, and activate both proliferative and anti-apoptotic effects, in an autocrine and/or paracrine manner ([@B106]). This phenomenon is known as "inside-out" signaling, and it has been described in cardiac myocytes too ([@B115]; [@B131]). Moreover, [@B3] demonstrated that SphK1 can be released outside the cells, thus accounting for the extracellular S1P generation. Conversely, SphK2 is primarily localized at the level of the endoplasmic reticulum (ER, [@B67]), or it can also be associated with mitochondria ([@B110]; [@B19]). S1P generated in these compartments can affect cell survival ([@B67]; [@B110]; [@B19]; [@B66]). Moreover, since SphK2 presents an NLS and NES, it can shuttle in and out of the nucleus. S1P generated in this subcellular compartment can affect histone deacetylases activity, with a consequently enhanced transcription of genes involved in the growth arrest ([@B38]).

Functional Role of SphK1
------------------------

As we learned before, it is generally well-consolidated that SphK1 is a cell survival promoter ([@B51]). Elevated cellular SphK1 levels appear to play a major role in enhanced proliferation and metastasis/invasion of several types of cancer cells ([@B137]; [@B48]; [@B61]; [@B103]; [@B92]). In this context, more than one study has demonstrated that inhibition of SphK1 has considerable potential as an anti-cancer strategy ([@B103]; [@B92]). Similarly, the downregulation of SphK1 has proven able to induce apoptosis and confer sensitivity to chemo- or radiation therapy of cancer cell lines ([@B6]; [@B103]; [@B37]; [@B92]). In line with these reports, ventricular cardiomyocytes and cardiac fibroblasts lacking SphK1 exhibit greater cell death when subjected to hypoxia, compared to wild-type (WT) controls ([@B3]; [@B115]). Interestingly, treatment of cardiomyocytes with exogenous S1P or with monoganglioside (GM-1), an acidic glycosphingolipid containing one sialic acid residue shown to elicit S1P generation ([@B17]), enhances the survival of both WT and SphK1 null cells ([@B3]; [@B115]). It is worth stressing that one of the proposed mechanism by which SphK1 controls cell death is the regulation of ceramide ([@B67]). In contrast to S1P, the ceramide-signaling molecule is able to exert pro-apoptotic actions. Its synthesis and accumulation are enhanced in cells lacking SphK1, while prevented in presence of high SphK1 levels ([@B67]). In 1996, in order to tie together the ability of S1P and ceramide to control cell fate, it has been coined the term "sphingolipid rheostat" ([@B22]; [@B79]). However, although SphK1 appears to play a major role in the regulation of this "rheostat," previous studies suggested that sphingolipid *per se* are able to influence the whole mechanism, thus including the "inside-out" one. In this context, [@B44] have recently shown that S1P can activate a positive feedback amplification loop via S1PRs activation and consequent increase in SphK1 expression.

Functional Role of SphK2
------------------------

Opposite to the protective role attributed to SphK1, several early studies examining SphK2's role have documented that the overexpression of this kinase induces cell cycle arrest and apoptosis ([@B51]). More in detail, SphK2 can inhibit cell growth and enhance apoptosis, in part by increasing ceramide production ([@B67]). Similarly, mitochondrial localization of SphK2, and specifically S1P generation at this site seems to contribute to the activation of the pro-death Bcl-2 family protein, BID, with subsequent mitochondrial membrane permeabilization and cytochrome *c* release ([@B110]; [@B19]). In keeping with this view, several reports have shown that downregulating SphK2 can effectively prevent the increase in apoptotic rates induced by the administration of either TNF-α or staurosporine ([@B135]; [@B42]). Interestingly, and contrary to the dogma that, differently from Sphka1, SphK2 is a pro-death factor, recent experimental evidence now supports a key role for this kinase in promoting cell survival and proliferation, much like SphK1 does in cancer cells, or even in cardiomyocytes ([@B134]; [@B35]; [@B126]). Consonant to this view, [@B134] have reported that the genetic ablation of SphK2 in MCF-7 breast tumor xenografts results in the inhibition of tumor growth. Moreover, in isolated murine hearts, Karliner and colleagues have shown that SphK2 is necessary for successful ischemic pre- and post-conditioning ([@B126]). Further to this, [@B35] also demonstrated that SphK2-evoked cardioprotection is dependent on the ability to prevent ischemia-induced mitochondrial dysfunction. Interestingly, the apparently divergent outcome reported with SphK2 studies could be ascribed to the specific subcellular localization of the enzyme. In agreement with this eventuality, studies have suggested that, when SphK2 is localized in the nucleus, it can inhibit the synthesis of DNA, thus exerting anti-proliferative effects ([@B38]). Conversely, other contributions have shown that, in human colon carcinoma cells, S1P generated by nuclear SphK2 can inhibit the retinoic acid receptor β, attenuating the tumor suppressor effects of this receptor ([@B102]).

S1P: Generation and Function
============================

S1P Biosynthesis
----------------

Given the variety of processes involving S1P, most cells---red blood cells, platelets, and vascular ECs, in particular---have all the enzymatic machinery necessary for S1P synthesis. Like other sphingolipids, S1P is derived from ceramide which is composed of a sphingosine base and an amide-linked acyl chain of variable length ([@B139]). Ceramide is in turn produced from the *de novo* synthetic pathway initiated by serine palmitoyltransferase in the ER, or from the degradation of some sphingolipids ([@B24]; [@B94]). The intracellular deacylation by ceramidase gives way to the formation of sphingosine and carboxylate ([@B84]). Then sphingosine can be phosphorylated to produce S1P (**Figure [1](#F1){ref-type="fig"}**). However, it is worth recalling that S1P levels in the cell are regulated not only by S1P biosynthetic enzymes but also by S1P degradative pathways, such as SPLs---two S1P-specific phosphatases---and by three lipid phosphate phosphatases (**Figure [1](#F1){ref-type="fig"}**; [@B39]).

![Schematic representation of S1PRs signaling activation in the cardiovascular system. Ceramide is catabolized by ceramidase to produce sphingosine that, in turn, is phosphorylated by sphingosine kinases 1 and 2 (SphK1 and 2) to generate the sphingosine 1-phosphate (S1P). Cellular S1P concentrations are regulated by the balance between its synthesis and de-phosphorylation mediated by S1P phosphatases (SPP). In the cytosol, S1P can also be irreversibly cleaved into *trans*-2-hexadecenal and ethanolamine phosphate or can be exported out of cells through the "inside-out" mechanism where it can bind three different receptors (S1PR~1-3~). Activation of S1PR~1~ induces negative inotropic effects via G protein (Gi) activation and decreased cAMP concentration. Moreover, S1PR~1~ is able to positively affect endothelial function and to confer protection to the heart, via activation of the mitogen-activated protein kinase 1 and 2 (ERK) and the protein kinase B (Akt). Both S1PR~2~ and S1PR~3~ activate Gi, Gq, and G12/13 appear to collaborate in providing cardioprotection and in regulating cardiac hypertrophy. However, while S1PR~2~ is involved in endothelial dysfunction and promotion of fibroblasts function, S1PR~3~ appears to influence the vascular tone and induce bradycardia.](fphar-08-00556-g001){#F1}

S1P Functions
-------------

In general, S1P cell death-suppressing and cell survival promoting effects are opposite to those typically attributed to ceramide that, almost invariably, induces apoptosis, senescence, autophagy, and growth arrest ([@B22]; [@B145]; [@B90]; [@B96]). Therefore, the intracellular synthesis of S1P vs. ceramide should be always under a tight control because any subtle change in this finely tuned balance, in response to environmental changes and stimuli, can direct cell in one direction or in the other ([@B22]; [@B145]; [@B90]; [@B96]). Along with this, SPL is able to promote apoptosis under stress conditions, reducing the circulating levels of S1P ([@B58]). Importantly, Karliner and colleagues have demonstrated that SPL activation in the myocardium following ischemia leads to reduced S1P levels and that knockout mice for this enzyme exhibit higher S1P levels and smaller infarct size ([@B5]). Moreover, mice null for SPL show significantly increased left ventricular function recovery over their WT infarcted counterparts ([@B5]). Thus, inhibition of SPL could represent a new target that can be utilized to prevent myocardium loss after ischemic injury.

S1P Levels as a Biomarker of Cardiovascular Disease
---------------------------------------------------

In light of the evidence discussed above, it is important to consider that blood plasma and serum typically contains, in principle, high levels of S1P ([@B77]; [@B23]). Importantly, changes in serum S1P may be a predictive marker for the presence and severity of cardiovascular disease, as in the case of obstructive coronary artery disease (CAD), atherosclerosis, myocardial infarction (MI) and HF in humans ([@B23]; [@B100]; [@B4]; [@B14]; [@B27]; [@B105]).

Accordingly, [@B55] reported a reduction in circulating S1P levels in patients with acute MI as compared to controls. Similarly, we have recently demonstrated, in mouse and rat models of post-ischemic HF, that either cardiac or circulating levels of S1P are reduced compared to non-ischemic controls ([@B14], [@B16]).

However, it is important to consider that a large amount (∼60--80%) of S1P in the human plasma is associated with high-density lipoprotein (HDL). The importance of HDL is mainly due to the actions exerted by this lipoprotein on S1P function. In this context, [@B136] demonstrated that HDL-S1P are able to induce a lower rate of internalization and degradation of S1PR~1~ than albumin-S1P (another carrier of S1P). Of note, HDLs are usually reduced in several diseases like atherosclerosis, CAD, MI, renal insufficiency, and diabetes ([@B100]), and this could influence the levels of circulating S1P. In the same vein, [@B100] reported that, in patients with CAD or MI, plasma S1P levels (normalized to HDL levels) were higher than in controls. However, in the same study, the authors analyzed the levels of HDL-S1P in MI and stable CAD patients, showing that the levels of S1P conjugated with this carrier were lower than in controls. In line with the latter evidence, [@B4] demonstrated that circulating S1P, dihydro-S1P and c24:1-ceramide levels in HDL correlate inversely with the incidence of ischemic heart disease.

S1P Receptors and Dependent Signaling in Cardiovascular System
==============================================================

Many of S1P actions are mediated through specific GPCRs. [@B36] demonstrated, for the first time, that S1P induced the activation of the extracellular signal-regulated kinase (ERK) 1/2 via Gi protein activation. Later on, [@B60] identified a GPCR, originally termed endothelial differentiation gene 1 (EDG1), as the receptor of S1P. Currently, five closely related GPCRs (S1PR~1-5~), which differ in tissue and cell expression, have been identified for their high affinity for this bioactive lipid ([@B20]). Importantly, while S1PR~1-3~ are mostly expressed in the cardiovascular, central nervous system, and immune system, S1PR~4~ is mainly present in the lymphoid tissue, whereas S1PR~5~ is predominantly expressed in the central nervous system, immune system (natural killer cells), and spleen ([@B128]; [@B91]; [@B46]). Importantly, the effects associated with S1PRs activation on different cell types in the cardiovascular system, either on cardiomyocytes, ECs, smooth muscle cells, or fibroblasts, are dictated by the specific G protein coupling. S1PR~1~ couples exclusively with the inhibitory G protein alpha subunit (Gαi), whereas S1PR~2~ and S1PR~3~ bind to Gαi, Gαq, and Gα13 and S1PR~4~ and S1PR~5~ couple to both Gαi and Gα13 ([@B70]). Following ligand binding and subsequent activation, the α subunit of the heterotrimeric G protein is released and interacts with its downstream effectors. The main effector for Gαi is the adenylate cyclase, which is inhibited, thus leading to a reduction of the second messenger cyclic adenosine 3′,5′-monophosphate (cAMP) ([@B10]). Moreover, Gαi is able to activate PKCα and 𝜀, thus modulating calcium uptake ([@B117]; [@B69]). In contrast, phospholipase C (PLC) mediates the response due to Gαq activation. In turn, PLC hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) to DAG and inositol trisphosphate (IP3) ([@B10]), whereas that for Gα13 and Gα12 is a Rho guanine nucleotide exchange factor (Rho-GEF), activating downstream low molecular Rho GTPases ([@B112]).

S1PRs in Vasculature
--------------------

S1P plays a key role in the development of the vasculature and its stabilization ([@B101]; [@B14]). Accordingly, S1P regulates the growth of ECs and vascular smooth muscle cells (VSMCs) ([@B104]; [@B101]; [@B52]). ECs express S1PR~1~, S1PR~2~, and S1PR~3~, with the isoform 1 being the most expressed subtype ([@B104]; [@B52]). For these reasons, it is not surprising that most of the S1P-mediated responses in these cells occur via S1PR~1~. Importantly, S1P regulates and stimulates the migration and proliferation of ECs and alteration in S1P levels or activity are responsible for aberrant vascular maturation ([@B52]). It has been shown, for instance, that the inability of S1P to activate the GTPase Rac, as observed in global S1PR~1~ knockout mice, is one of the mechanisms associated with the impaired vasculature development and embryonic lethality ([@B64]). At this regard, in this study, the authors suggest that the alteration of S1PR~1~ activation on ECs could negatively affect VSMCs recruitment ([@B64]). Importantly, in addition to S1PR~1~ binding in ECs, S1P also activates the S1PR~3~ eliciting important vascular processes, such as the formation of new vessels and stabilization of barrier integrity ([@B127]). For example, it has been shown that S1P-mediated migration proliferation and vasculature formation require both the S1PR~1~ mediated activation of Gi protein and the S1PR~3~ coupling to Gq/G12,13 ([@B112]; [@B57]; [@B127]). The S1PR~3~ requirement has been further validated in studies demonstrating that a peptide derived from the second intracellular loop of the S1PR~3~ can induce pro-angiogenic responses ([@B62]). Conversely, the activation and upregulation of S1PR~2~ has been associated with impaired functions in ECs, i.e., chemotactic, wound healing, and morphogenic responses ([@B65]; [@B143]). In particular, [@B65] have recently demonstrated *in vivo* that, in aging rats, S1PR~2~, like others GPCRs ([@B121]; [@B29]), takes part in senescence-mediated endothelial dysfunction and aging processes ([@B143]).

Interestingly, in VSMCs the expression pattern for S1PRs significantly differs from that of ECs ([@B127]; [@B52]). VSMCs mainly express the S1PR~2~ and S1PR~3~ ([@B127]; [@B52]). While S1PR~3~ stimulation increases the activity of Rac with an increased VSMCs migratory capacity, the activation of S1PR~2~ inhibits Rac via Rho/Rho kinase pathway, thus leading to a significant reduction in VSMCs function ([@B127]; [@B113]; [@B52]). Importantly, S1PR~3~ appears to be the major mediator of S1P-induced vasoconstriction because this lipid fails to increase the vascular tone in arteries isolated from S1PR~3~ knockout mice ([@B97]).

S1PRs in the Heart
------------------

Myocytes and fibroblasts represent the vast majority of the myocardial tissue. Importantly, due to the elevated activity expression of SphKs, fibroblasts appear to be the major source of cardiac S1P ([@B49]). Cardiac fibroblasts express predominantly S1PR~3~, with much lower levels of S1PR~1~ and S1PR~2~ being expressed ([@B59]). However, most of the effects on fibroblasts function have been attributed to S1PR~2~ activation ([@B129]; [@B81]; [@B119]). In particular, S1P is a positive regulator of fibroblasts function and proliferation, and these effects are associated with the activation of ERK and Rho activity downstream of S1PR~2~ ([@B129]; [@B81]; [@B119]). Differently from fibroblasts, in cardiomyocytes, S1PR~1~ is the predominant S1P receptor subtype expressed ([@B71]; [@B14]). Initially, several studies evaluated the effect on S1PR~1~ on ion channels and contractility ([@B70]), but decades of discoveries have later revealed that this receptor has also a prominent role in hypertrophic response and cardioprotection ([@B70]).

S1P-dependent activation of S1PR~1~ in cardiomyocytes is necessary for heart development in mice ([@B21]). In fact, [@B21] have recently shown that conditional knockout mice for S1PR~1~ show ventricular septal defects and perinatal lethality. Moreover, these authors reported that lacking S1PR~1~ is associated with decreased myofibril organization ([@B21]). Similarly, [@B53] have shown that cardiomyocyte-restricted deletion of S1PR~1~ in mice results in progressive cardiomyopathy, compromised response to β-adrenergic receptor (βAR) stimulation and premature death.

The S1PR~1~ in cardiomyocytes is also a major regulator of contractile response ([@B70]). Indeed, it counters the mechanical effects (positive inotropy/lusitropy, etc.) that follow cardiac β~1~-adrenergic receptor (β~1~AR)-agonism ([@B70]; [@B14]). Accordingly, S1P treatment of ventricular myocytes blocks the effects produced by the β~1~/β~2~AR agonist, isoproterenol, preventing the activation of adenylate cyclase, thus leading to a negative inotropic response ([@B71]). This functional interaction between βAR and S1PR~1~ signaling *in vivo* was more recently reported also by [@B28]. In their study, these authors demonstrated that βAR-agonism in mice results in cardiac hypertrophic response via engagement of the S1PR~1~ signaling pathway ([@B28]). We recently proposed that this cross-talk is a major protective mechanism in response to myocardial ischemia ([@B14]). In fact, we showed that isoproterenol stimulation of H9c2 cells induces the activation of S1PR~1~ pro-hypertrophic signaling ([@B14]). *In vivo*, we observed that, following a cardiac ischemic attack, increased circulating levels of catecholamines lead to β~1~AR hyperactivation and subsequent desensitization/downregulation ([@B14]), an effect coupled to increased GPCR kinase 2 (GRK2) levels that regulate both the β~1~AR and S1PR~1~ ([@B14]). Importantly, the activation of such signaling pathway leads to the reciprocal downregulation of β~1~AR and S1PR~1~ in cardiac myocytes, leading to worse remodeling and progression toward HF ([@B14]). This study further supported the idea that blockade of GRK2 is a valid strategy to prevent HF development and progression, but also demonstrated the cardioprotective role of S1PR~1~ ([@B12], [@B11],[@B13]; [@B9]). In line with these data, we recently reported that activation of S1PR~1~ in the heart is also modulated by the β~3~AR ([@B16]). This receptor is the less βAR isoform expressed in the heart; however, it has important regulatory activities in cardiac hypertrophic response and in contractility ([@B10]). In line with a previous study in adipocytes ([@B142]), we demonstrated that selective β~3~AR stimulation leads to SphK1 upregulation and S1P release with a subsequent activation of S1PR~1~ in cardiomyocytes ([@B16]). Again, this mechanism appears to be relevant in a post-ischemic HF animal model. In fact, re-activation of β~3~AR via β1-AR blockade (Metoprolol), an indirect agonist of β~3~AR, is able to promote the activation of S1PR~1~ thus protecting the heart from failure ([@B16]).

Importantly, as discussed above, S1P is a cardioprotective molecule which signals in the heart via S1PRs. However, despite decades of studies from several groups, including ours, suggesting that S1PR~1~ is the major player in S1P-dependent cardioprotection ([@B12], [@B16]; [@B51]; [@B69]), some reports have indicated that S1PR~2~ and S1PR~3~ can also take part in these protective molecular mechanisms activated in the myocardium in response to a specific injury ([@B116]; [@B72]; [@B70]; [@B76]; [@B95]; [@B140]). In particular, mice lacking either S1PR~2~ or S1PR~3~, following an ischemic insult, develop infarcts equivalent to those of WT mice, whereas in S1PR2 and 3 double-knockout mice, the infarct size was increased by more than 50%, thus suggesting the potential role of these two receptors in protecting cardiomyocytes ([@B72]). Mechanistically, all the beneficial effects associated with S1PR~1-3~, appear to be dependent mainly on the protein kinase B (Akt), that, via augmentation of eNOS expression/activity, has multiple effects, such as induction of adaptive hypertrophy, modulation of angiogenesis, and inhibition of apoptosis ([@B68]; [@B70]; [@B18]; [@B15]; [@B53]). Moreover, it is also worth noting that recent reports suggest a protective role for RhoA activation in the heart ([@B138]; [@B144]; [@B140]) which do not involve S1PR~1~ (**Figure [1](#F1){ref-type="fig"}**).

Targeting S1Prs and SphKs as a Therapeutic Strategy in Cardiovascular Disorders
===============================================================================

Currently, the majority of drugs targeting the S1P signaling are directed to the S1PRs rather than the ligand. This is due to the fact that, as anticipated above, almost all S1P actions are mediated by its receptor. Moreover, targeting a specific S1PR would render a given drug highly selective. For these reasons, many agonists/antagonists of the S1PRs have been developed and studied. For some of them, clinical data on are also available (Amiselimod, Siponimod, Ozanimod, Ceralifimod, GSK2018682, Ponesimod; [@B82]; [@B111]). One of the most tested S1PR agonists is Fingolimod or FTY720. This compound is a structural homolog of S1P, which is phosphorylated by SphK2 to form Fingolimod-phosphate (Fingolimod). It serves as a potent agonist of S1PR~1~ ([@B68]; [@B40]), or as a SphK1 inhibitor ([@B118]). Of relevance, this compound is a US Food and Drug Administration (FDA) approved the drug for the treatment of multiple sclerosis ([@B46]; [@B86]). In fact, although the Fingolimod-phosphate initially activates S1PR~1~, on lymphocytes, it subsequently can induce the receptor downregulation thus preventing the egress of these cells from lymphoid tissues ([@B68]; [@B46]; [@B86]). This double mechanism of action (agonism/antagonism) of Fingolimod on S1PR~1~ reduces the infiltration of lymphocytes into the central nervous system blocking their noxious effect ([@B68]; [@B46]; [@B86]).

S1P and Protection Against Myocardial Ischemia
==============================================

S1P is formed in the ischemic myocardium, and it is thought to be cardioprotective, mimicking the effects of ischemic preconditioning via a PKC𝜀-dependent pathway ([@B47]; [@B124]; [@B69]). Importantly, as suggested by several studies in cardiac and non-cardiac cells, these beneficial effects are induced mainly by the selective binding to S1PR~1~. In line with this possibility, studies have evaluated the potential protective effect of S1PR~1~ agonism in cardiac cells. For instance, [@B130] demonstrated that Fingolimod increases survival in adult murine cardiac myocytes subjected to hypoxia by inhibiting apoptosis. Following *in vivo* studies have demonstrated cardioprotective effects exerted by S1PR~1~ via Fingolimod stimulation. In particular, reports have shown that this drug is able to reduce ischemia/reperfusion (I/R) injury and to improve myocardial function in isolated mouse and rat heart preparations ([@B43]; [@B26]; [@B125]). Further to this, in a mouse model of myocardial I/R, [@B34] have shown that, when given at reperfusion, Fingolimod provides a better hemodynamic outcome as compared to placebo-treated animals. Importantly, this effect was associated with a reduction in the number of phagocytic monocytes invading the myocardium ([@B34]). Furthermore, in a recent report, [@B99] have demonstrated that Fingolimod improves myocardial function after MI in pigs. In this study, the authors showed that Fingolimod administration was associated with a reduction in the cardiac hypertrophic response and interstitial fibrosis in the remote, non-ischemic myocardium ([@B99]). However, it is worth noting that in addition to S1PR~1~ activity modulation, studies have demonstrated that, albeit with minor affinity, Fingolimod can also bind and activate S1PR~3~ ([@B68]; [@B40]; [@B51]). For this reason, in light of this evidence, one question would be whether or not Fingolimod induces its effects and if these are really due to the only S1PR~1~ modulation or if they are also related to S1PR~3~. Answering this intriguing would require fully dedicated studies. Anyway, other reports concerning the S1PR~1~ agonism protective effects against ischemic injury have explored the role of these receptors also in other organs, such as the brain and the lung ([@B108]; [@B8]). In particular, [@B108] have demonstrated that selective stimulation of S1PR~1~, via Fingolimod or VPC01091, provided comparable protection from a lung injury and dysfunction after I/R. Further, in a mouse model of stroke, [@B8] demonstrated the potential of S1PR~1~ agonists, such as LASW1238 or Fingolimod, in reducing the infarct size. Importantly, the authors concluded that these two drugs protect the brain only when lymphopenia is sustained for at least 24 h ([@B8]). In aggregate, these studies strongly support the overall notion that pharmacological activation of S1PR~1~ can reduce the detrimental effects of acute ischemia in an experimental setting, as demonstrated both in small and in large-animal models.

Use of S1PR~1~ Agonism in Humans: Any Alternative to Fingolimod?
----------------------------------------------------------------

Although promising, the utilization of Fingolimod in humans raises some concerns. For instance, [@B98] demonstrated that stimulation with a non-selective S1PR agonist reduced heart rate (bradycardia) in WT mice, but not in S1PR~3~ KO animals. Moreover, Fingolimod is a well-known activator of both S1PR~1~ and S1PR~3~; hence, it has been suggested that behind direct S1PR~1~ activation, Fingolimod can also induce bradycardia via S1PR~3~ ([@B51]). However, data obtained in rats by [@B30] show that Fingolimod-induced bradycardia requires only S1PR~1~. In line with this evidence, [@B32] showed that an S1PR~1~ selective ligand causes transient bradycardia in humans. Taking all this into account, the FDA revised the recommendations for cardiovascular monitoring in patients with multiple sclerosis receiving Fingolimod. Most importantly, in a recent study, [@B93] demonstrated that in multiple sclerosis patients this pharmacological agent reduces left ventricular systolic function. Therefore, based on the beneficial effects exerted by S1PR~1~, it is plausible that this adverse event could be related to the antagonistic effect of the Fingolimod on S1PR~1~ (**Figure [2](#F2){ref-type="fig"}**). Therefore, other drugs or therapeutic strategies directed to improve S1P signaling/function are currently under evaluation. For instance, [@B111] have recently tested the effects and the efficacy of Amiselimod, a second-generation S1P receptor modulator that is highly selective for S1PR~1~ and S1PR~5~, with no distinct agonist activity for S1PR~2~ or S1PR~3~. Importantly, compared to Fingolimod, this compound appears to be safer because it failed to induce bradycardia ([@B111]). In an alternative to approaches directed to modulate S1P signaling, [@B25] have recently demonstrated that intracardiac injection of adenoviral vectors encoding for SphK1 markedly reduces myocardial infarct size, in a rat model of I/R injury. Of note, the overexpression of SphK1 results in a significant improvement in left ventricular systolic pressure and end-diastolic pressure, and better contractility ([@B25]). Alternatively, we recently demonstrated that restoration of cardiac plasma membrane levels of S1PR~1~, via a recombinant adeno-associated virus serotype 6 (AAV6), produces beneficial effects, in a HF rat model ([@B14]). Importantly, the overexpression of S1PR~1~ improves both cardiac function and enhances the re-vascularization of the ischemic cardiac tissue ([@B14]).

![Cardiac effects associated with Fingolimod-mediated activation of S1PR~1~ and S1PR~3~. Fingolimod is phosphorylated by sphingosine kinase 2 (SphK2) to generate Fingolimod-phosphate (Fingolimod) that in turn binds to S1PR~1~. However, the sustained stimulation leads to S1PR~1~ internalization and degradation and to sphingosine kinase 1 (SphK1) inhibition. These effects are probably related to an impairment of the function of the left ventricle (LV). Moreover, via binding and activation of S1PR~3~, Fingolimod can induce bradycardia.](fphar-08-00556-g002){#F2}

Conclusion
==========

The GPCRs are cell surface receptors that mediate fundamental processes in all cell types of the cardiovascular system. Therefore, it is not surprising that these receptors are currently the largest family of targets for drugs in clinical use. Accordingly, approximately 20% of medicaments used to treat cardiovascular disorders have GPCR-binding properties. Importantly, the discovery that S1P signals via GPCRs, influencing the entire mammal physiology---from the immune to the nervous system, from the circulation to the skeletal muscle apparatus---have significantly advanced the field of cardiovascular pharmacology. Several drug candidates, targeting both S1PRs and downstream molecules, are currently undergoing clinical trials, and novel compounds of diverse pharmacodynamics have been identified in the attempt to optimize the benefits afforded by S1PR~1~ stimulation during the course of acute and chronic cardiac diseases.
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